MAY 20, 2022 1:38 PM PDT

Drug Shows Promise in treating Spinal Cord Injury

WRITTEN BY: Annie Lennon

A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord injury (SCI). The corresponding study was published in Clinical and Translational Medicine

"There is currently no reparative drug available for SCI patients. Treatments only provide symptomatic relief and do not tackle the underlying molecular mechanisms that cause or contribute to oedema and blood-spinal cord barrier breakdown, "said Professor Zubair Ahmed, Professor of Neuroscience and lead for the Neuroscience and Ophthalmology Section at The University of Birmingham, and lead author of the study. 

"This drug has the potential to be a first-in-class treatment against some of the key pathological drivers of SCI and could revolutionize the prospects for recovery of SCI patients," he added. 

The drug is called AZD1236, and is a selective inhibitor of two enzymes- MMP-9 and MMP-12- that play a role in the inflammatory process. In the present study, the researchers tested the drug in mouse models of spinal cord injury. 

In doing so, they found that AZD1236 led to an 85% improvement in movement and sensation after only three days of treatment, beginning 24 hours post-injury. They further found that at three weeks, mice treated with the drug showed an 'unprecedented' recovery. In contrast, control animals still demonstrated significant deficits at six weeks post-injury. 

In terms of biomarkers, the researchers found that oral dosing of AZD1236 reduced enzyme activity by 90% in serum and 69-74% in cerebrospinal fluid. Intrathecal injection- injection around the spinal cord- reduced enzyme activity by 88-90% in the cerebrospinal fluid. 

The drug also suppressed the production of pro-inflammatory cytokines- known to contribute to long-lasting neuropathic pain- by 85-95%, and was 82% more effective than current treatments such as pregabalin and gabapentin in reducing neuropathic sensitivity to cold, heat, and touch. 

"Exploring the potential of AZD1236 for this new indication represents a great outcome for our Open Innovations programme and aligns with our ethos of "sharing ideas and enabling scientific innovation to cross boundaries between academia and industry will help to translate innovative ideas into scientific breakthroughs and potential new medicines more quickly," said Hitesh Sanganee Ph.D, Head of Emerging Innovations at AstraZeneca. 

 

Sources: Clinical and Translational Medicine, Science Daily

 

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 26, 2022
Immunology
Unraveling the Mystery of an Immune Cell Checkpoint
APR 26, 2022
Unraveling the Mystery of an Immune Cell Checkpoint
The immune system can get tired when it has to fight against a chronic infection or a disease like cancer. Exhausted T c ...
MAY 13, 2022
Drug Discovery & Development
Promising New Treatment for Cat Litter Parasite T. Gondii
MAY 13, 2022
Promising New Treatment for Cat Litter Parasite T. Gondii
Researchers have discovered a promising therapy for those suffering from toxoplasmosis, a disease caused by a parasite l ...
MAY 25, 2022
Cannabis Sciences
NYU Researchers Find CBD effectively Reduces Post Operative Pain
MAY 25, 2022
NYU Researchers Find CBD effectively Reduces Post Operative Pain
  An NYU research study found that a cannabidiol (CBD) tablet safely and effectively reduced post-operative pain. T ...
JUN 06, 2022
Drug Discovery & Development
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
JUN 06, 2022
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
A new class of antibiotics has shown promise in preclinical trials against drug-resistant tuberculosis. The correspondin ...
JUN 15, 2022
Plants & Animals
Using Mosquito Spit to Develop Vaccines for Zika, Yellow Fever, Dengue
JUN 15, 2022
Using Mosquito Spit to Develop Vaccines for Zika, Yellow Fever, Dengue
Mosquitoes, specifically, the Aedes mosquito, can carry and transmit deadly virsues like the Zika virus and the viruses ...
JUN 27, 2022
Plants & Animals
Developing a New Approach to Rabies Vaccination
JUN 27, 2022
Developing a New Approach to Rabies Vaccination
Rabies is a viral disease that can spread through the saliva. Several kinds of animals can get rabies, including humans ...
Loading Comments...